Mankind Pharma (BOM:543904) Asset Impairment Charge : ₹0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma Asset Impairment Charge?

Mankind Pharma's Asset Impairment Charge for the three months ended in Mar. 2024 was ₹0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was ₹0 Mil.

Mankind Pharma Asset Impairment Charge Historical Data

The historical data trend for Mankind Pharma's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma Asset Impairment Charge Chart

Mankind Pharma Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Asset Impairment Charge

Mankind Pharma Quarterly Data
	Mar20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial							-	-	-	-	-

Mankind Pharma Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Mankind Pharma Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Mankind Pharma (BOM:543904) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (BOM:543904) » Definitions » Asset Impairment Charge

Traded in Other Exchanges

MANKIND:India

Address

262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020

Website

https://www.mankindpharma.com

Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (BOM:543904) Headlines

No Headlines